Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue

Patent Citations (55)

Non-Patent Literature (106)

• “S-Adenosylmethionine”; Arthritis Network: Third Edition, Aug. 1998, 9-10.Applicant
• Bassleer C., Henrotin Y., Franchimont, P., “In-Vitro Evaluation of Drugs Proposed as Chondroprotective Agents”, International Journal of Tissue Reactions, 14[5](1992) 231-241.Applicant
• Calia, Kurt Geoffrey; Cover Letter to USPTO with Jan. 11, 1996 date stamp indicating receipt of Petition to Make Special and the documentation in support of that petition; pp. 1-2.Applicant
• Calia, Kurt Geoffrey; Petition to Make Special; Jan. 11, 1996; pp. 1-2.Applicant
• Henderson, Robert J.; Declaration by Applicant in Support of Petition to Make Special ; Jan. 2, 1996; pp. 1-5, Exhibits A, B, C, and D.Applicant
• Calia, Kurt Geoffrey; Declaration by Attorney in Support of Petition to Make Special; Jan. 11, 1996; pp 1-3.Applicant
• Vidal y Plana et al, “Articular Cartilage Pharmacology: I. In Vitro Studies on Glucosamine and Non-Steroidal Anti-inflammatory Drugs,” Pharmacological Research Communications, 10 (6) 557-569 (1978).Applicant
• Murray, “A Natural Treatment of Osteoarthritis,” MPI's Dyanmic Chiropratic, pp. 8-10, Sep. 12, 1993.Applicant
• Morrison et al, “Coronary Heart Disease and the Mucopolysaccharides (Glycosaminoglycans),” C.C. Thomas, Publisher, 1973, pp. 12-13; 109-127.Applicant
• Christensen, “Nutritional Support For Injury Rehabilitation Specific Needs For The Three Phases of Rehabilitation,” Chiropractic Products, pp. 100-102 (Apr. 1993).Applicant
• Stramentinoli, G., “Pharmacologic Aspects of S-Adenosylmethionine,” American Journal of Medicine, 83 (Supp. 5A): 35-42 (1987).Applicant
• Adachi et al, “The Effects of S-adenosylmethionine on Intrahepatic Cholestasis,” Japan Arch. Int. Med., 33(6): 185-192 (1986).Applicant
• Caruso et al, “Antidepressant Activity of S-adenosylmethionine,” Lancet, 904 (1984).Applicant
• Domljan et al, “A Double-blind Trial of Ademetionine vs Naproxen in Activated Gonarthrosis,” Int. Journal of Clinical Pharmacology, Therapy and Toxicology, 27 (7): 329-333 (1989).Applicant
• Feo et al, “Early Stimulation of Polyamine Biosynthesis During Promotion by Phenobarbital of Diethylnitrosamine-induced Rat Liver Carcinogenesis: The Effects of Variations of the S-adenosyl-L-methionine Cellular Pool,” Carcinogenesis, 6 (12): 1713-20 (1985).Applicant
• Garcea et al, “Variations of Ornithine Decarboxylase Activity and S-adenosyl-L-methionine and 5′-methylthioadenosine Contents During the Development of Diethylnitrosamine-induced Liver Hyperplastic Nodules and Hepatocellular Carcinoma,” Carcinogenesis, 8 (5): 653-58 (1987).Applicant
• Schumacher, “Osteoarthritis: The Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine,” American Journal of Medicine, 83 (Supp. 5A): 1-4 (1987).Applicant
• Frezza et al, “Oral S-Adenosylmethionine in the Symptomatic Treatment of Intrahepatic Cholestasis,” Gastroenterology, 99: 211-215 (1990).Applicant
• Matthews & Lewis, “The Anti-inflammatory Action of S-adenosyl-L-methionine,” Pharmacol. (Life Sci. Adv.), 9: 145-152 (1990).Applicant
• Szabo et al, “Sulfhydryl Compounds May Mediate Gastric Cytoprotection,” Science, 214: 200-202 (Oct. 1981).Applicant
• Conroy et al, “Occurrence of Ornithine Decarboxylase and Polyamines in Cartilage,” Biochem. J., 162: 347-350 (1977).Applicant
• Bird et al, “Putrescine—A Potent Endogenous Anti-inflammatory Substance in Inflammatory Exudates,” Agents and Actions, 13: 342-347 (1983).Applicant
• Oyanagui, “Anti-inflammatory Effects of Polyamines in Serotonin and Carrageenan Paw Edemata—Possible Mechanism to Increase Vascular Permeability Inhibitory Protein Level Which is Regulated by Glucocorticoids and Superoxide Radical,” Agents and Actions, 14: 228-237 (1984).Applicant
• Kafy et al, “In Vitro Interactions Between Endogenous Polyamines and Superoxide Anion,” Agents and Actions, 18: 555-559 (1986).Applicant
• Vendemiale et al, “Effects of Oral S-Adenosyl-L-Methionine on Hepatic Glutathione in Patients with Liver Disease,” Scand. J. Gastroenterol., 24: 407-415 (1989).Applicant
• Kaye et al, “Metabolism of Exogenous S-Adenosyl-L-Methionine in Patients with Liver Disease,” Drugs, 40 (Supp. 3): 124-138 (1990).Applicant
• “Current Therapy in Equine Medicine 2,” Robinson, Editor, W.B. Saunders Co., Publisher, pp. 402-403 (1987).Applicant
• Joosten et al, “Metabolic Evidence That Deficiencies of Vitamin B-12 (Cobalamin), Folate, and Vitamin B-6 Occur Commonly in Elderly People,” Am. J. Clin. Nutr., 58: 468-76 (1993).Applicant
• Chen and Whanger, “Effect of Vitamin B-12 Status on Selenium Methylation and Toxicity in Rats: In Vivo and In Vitro Studies,” Toxicology and Applied Pharmacology, 118: 65-72 (1993).Applicant
• Drovanti et al, “Therapeutic Activity of Oral Glucosamine Sulfate in Osteoarthrosis: A Placedbo-Controlled Double-Blind Investigation,” Clinical Therapeutics, 3 (4): 260-272 (1980).Applicant
• Karzel and Domenjoz, “Effects of Hexosamine Derivatives and Uronic Acid Derivatives on Glycosaminoglycane Metabolism of Fibroblast Cultures,” Pharmacology 5: 337-345 (1971).Applicant
• Setnikar et al, “Pharmacokinetics of Glucosamine in the Dog and in Man,” Arzneim.-Forsch., 36 (I): 729-735 (1986).Applicant
• Anon., “Using a Chondroprotective Drug in Treating Dogs with Osteochondrosis,” Veterinary Medicine, 130 (Feb. 1993).Applicant
• Bucci, “Manganese: Its Role in Nutritional Balance,” Today's Chirop., 17 (2): 23-28, 44 (1988).Applicant
• Garrison, Jr., et al, “The Nutrition Desk Reference,” Keats Publishing, Inc., pp. 70-71 (1985).Applicant
• Champe et al, Lippincott's Illustrated Reviews: Biochemistry, pp. 148-150 (2nd ed. 1994).Applicant
• Bucci,“Nutrition Applied to Injury Rehabilitation and Sports Medicine,” CRC Press, Inc. (1994).Applicant
• Hardingham et al, “Proteoglycans: Many Forms and Many Functions,” 6 FASEB J. 861, 862 (1992).Applicant
• Banks, “Applied Veterinary Histology,” Williams and Wilkins Publisher, pp. 84-85 (1986).Applicant
• Bucci, “Glucosamine—A New Potent Nutraceutical for Connective Tissues,” Nutritional Supplement Advisor (Jul. 1992).Applicant
• Bucci, “Chondroprotective Agents Glucosamine Salts and Chondroitin Sulfates,” Townsend Letter for Doctors, pp. 52-54 (Jan. 1994).Applicant
• McGarrity et al, “Effect of Selenium on Growth, S-Adenosylmethionine and Polyamine Biosynthesis in Human Colon Cancer Cells,” Anticancer Research, 13: 811-815 (1993).Applicant
• Dausch et al, “Increased Levels of S-Adenosylmethionine in the Livers of Rats Fed Various Forms of Selenium,” Nutrition and Cancer, 20 (1): 31-39 (1993).Applicant
• Kajander et al, “Effects of Selenomethionine on Cell Growth and on S-adenosylmethionine Metabolism in Cultured Malignant Cells,” Biochem. J., 267: 767-774 (1990).Applicant
• Barak et al, Alcoholism: Clin. and Exp. Res., 17(3): 552-555 (1993).Applicant
• Golding and Ghosh, Current Therapeutic Res., 33: 173-184 (1983).Applicant
• Engel and Juhran, Arztl. Praxis., 34(51): 2010 (1982). (Translation-Abstract Only).Applicant
• Rejholec, V. MD, “Long-Term Studies of Antiosteoarthritic Drugs: An Assessment,” Seminars in Arthritis and Rheumatism, vol. 17, No. 2, Suppl. 1 (Nov), 1987; pp. 35-53.Applicant
• “Joint Lameness,” AAEP Proceedings, vol. 42, 1996, pp. 116-117.Applicant
• “Clinical Section—Expert Review,” pp. 1-23, 1997.Applicant
• Moskowitz, Roland W., “Primary Osteoarthritis: Epidemiology; Clinical Aspects and General Management,” Osteoarthritis: The Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 5.Applicant
• Fassbender, Hans G., “Role of Chondrocytes in the Development of Osteoarthritis,” Osteoarthritis: The Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 17.Applicant
• McCarty, M.F., “The Neglect of Glucosamine as a Treatment for Osteoarthritis—A Personal Prospective,” Medical Hypotheses, (1994), 42, 323-27.Applicant
• Bassleer, Corinne, et al., Proteoglycans Synthesized by Human Chondrocytes Cultivated in Clusters, Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 25.Applicant
• Brandt, Kenneth D., Effects of Nonsteroidal Anti-Inflammatory Drugs on Chondrocyte Metabolism in Vitro and in Vivo, Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 29.Applicant
• Laudanno, Oscar M., “Cytoprotective Effect of S-Adenosylmethionine Compared with That of Misoprostol against Ethanol-, Aspirin-, and Stress-Induced Gastric Damage,” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 43.Applicant
• Harmand, Marie-Francoise, et al., “Effects of S-Adenosylmethionine on Human Articular Chondrocyte Differentiation: An in Vitro Study,” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 48.Applicant
• Barcelo, Hector A., “Effect of S-Adenosylmethionine on Experimental Osteoarthritis in Rabbits,” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 55.Applicant
• Di Padova, Carlo, “S-Adenosylmethionine in the Treatment of Osteoarthritis: Review of the Clinical Studies,” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 60.Applicant
• Caruso, Innocenzo, et al., “Italian Double-Blind Mulicenter Study Comparing S-Adenosylmethionine, Naproxen, and Placebo in the Treatment of Degenerative Joint Disease,” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 66.Applicant
• Maccagno, Armando, et al., “Double-Bind Controlled Clinical Trial of Oral S-Adenosylmethionine verus Piroxicam in Knee Osteoarthritis,” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 72.Applicant
• Vetter, Georg, “Double-Blind Comparative Clinical Trial with S-Adenosylmethionine and Indomethacin in the Treatment of Osteoarthritis,” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 78.Applicant
• Muller-Fassbender H., “Double-Blind Clinical Trial of S-Adenosylmethionine versus ibuprofen in the Treatment of Osteoarthritis,” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 81.Applicant
• Berger, Rainer, et al., “A New Medical Approach to the Treatment of Osteoarthritis: Report of an Open Phase IV Study with Ademetionine (Gumbaral),” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 84.Applicant
• Konig, Benno, “A Long-Term (Two Years) Cliinical Trial with S-Adenosylmethionine for the Treatment of Osteoarthritis,” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 89.Applicant
• Baldessarini, Ross J., “Neuropharmacology of S-Adenosyl-L-Methionine,”Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 95.Applicant
• Carney, Michael W. P., et al., “S-Adenosylmethionine and Affective Disorder,” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 104.Applicant
• Tavoni, Antonio, et al., “Evaluation of S-Adenosylmethionine in Primary Fibromyalgia: A Double-Bline Crossover Study,” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83 (5A), Nov. 20, 1987 at 107.Applicant
• Holme, E., et al., “Betaine for Treatment of Homocystinuria Caused by Methylenetetrahydrofolate Reductase Deficiency,” Archives of Disease in Childhood, 1989 (64) at 1061-64.Applicant
• “Vetrazene” Literature, Vetraceutical Services, Inc., 1996.Applicant
• vol. 87:9789(x), Chem Abs. (1977).Applicant
• vol. 74:11643(r), Chem Abs. (1971).Applicant
• vol. 78:15438(b), Chem. Abs. (1973).Applicant
• vol. 76:41905(m), Chem. Abs. (1972).Applicant
• Read, RA, et al., “Systemic use of pentosan polysulphate in treatment of Osteoarthritis,” Journal of Small Animal Practice. 37:108-114 (1996).Applicant
• Burkhardt, P., et al., “Laboratory evaluation of anti-arthritic drugs as potential chondroprotective agents,” Semin. Arthritis Rhum. 17 (suppl.):3-34 (1987).Applicant
• Goad, Cathryn E., et al., “Pentosan-induced thrombocytopenia: Support for an immune complex mechanism,” British Journal of Hematology, 88:803-08 (1994).Applicant
• Ghosh, P., et al., “Animal models of early Osteoarthritis: Their use for evaluation of potential chondroprotective agents,” Agents and Actions. Suppl. 39:195-206, (1993).Applicant
• Collier, S., et al., “Evaluation of effects of antiarthritic drugs on the secretion of proteoglycans by lapine chondrocytes using a novel assay procedure,” Annal of Rheumatic Diseases, 4: 372-381 (1989).Applicant
• Francis, DJ, et al., “Pentosan polysulphate and glycosaminoglycan polysulphate stimulate the synthesis of hyaluronan in vivo,” Rheumatology International, 13(2):61-4 (1993).Applicant
• Ghosh, P., “Anti-rheumatic drugs and cartilage,” Bailliere's Clinical Rheumatology, 2(2):309-338 (1988).Applicant
• Hutadilok N., et al., “Pentosan polysulphate stimulates hyaluronate and DNA synthesis in synovial fibroblasts and partially reduces the supportive effect of hydrocortisone on fibroblast metabolism,” Current Therapeutic Research 44:845-860 (1988).Applicant
• Andrews, JL, et al., The interaction of pentosan polysulphate (SP54) with human neutrophil elastase and connective tissue matrix components, Chemical and Biological interactions, 47:157-73 (1983).Applicant
• Rogachefsky, RA, et al., “Treatment of canine osteoarthritis with insulin-like growth factor-1 (IGF-1) and sodium pentosan polysulfate,” Osteoarthritis and Cartilage, 1:105-14 (1993).Applicant
• Ghosh, P., et al., “Second-Line agents in osteoarthritis,” Second-Line Agents in the Treatment of Rheumatic Diseases (Marcel Dekker, Inc., New York) pp. 363-427 (1992).Applicant
• Bansal, M., et al., “The effects of calcium pentosan polysulfate on inflammatory mediators in the rat air-pouch model of inflammation,” Current Therapeutic Research 546: 714-730 (1993).Applicant
• Kalbhen, DA, “Pharmacological studies on the anti-inflammatory effect of a semi-synthetic polysaccharide (pentosan polysulfate),” Pharmacology 9: 74-79 (1973).Applicant
• Klocking, HP, et al., “Effect of sodium pentosan polysulphate on the thrombogenicity of prothrombin complex concentrates,” Thrombosis Research, 67(1): 41-48 (1992).Applicant
• Srivastava, AK, et al., “Pentosan polysulfate, a potent anti-HIV and anti-tumor agent, inhibits protein serine/threonine and tyrosine kinases,” Molecular and Cellular Biochem,. 120(2):127-33 (Mar. 24, 1993).Applicant
• Senthil, D., et al., “Influence of sodium pentosan polysulphate and certain inhibitors calcium oxalate crystal growth,” Molecular and Cellular Biochemistry 156(1):31-5 ( Mar. 9, 1996).Applicant
• Hampson, SJ, et al., “Sodium pentosanpolysulphate in the management of haemorrhagic cystitis: Experience with 14 patients,” European Urology 25(1):40-2 (1994).Applicant
• Tardy-Poncet, B., et al., “Pentosan polysulfate-induced thrombocytopenia and thrombosis,” American Journal of Hematology, 45(3):252-7 (Mar. 1994).Applicant
• Verbruggen,G., et al., “Intra-articular injection of pentosanpolysulphate results in increased hyaluronan molecular weight in joint fluid,” Clinical and Experimental Rheumatology 10(3):249-54 (May-Jun. 1992).Applicant
• Maffrand, J.P., et al., Seminar in Thrombosis and Hemostasis, “Experimental and Clinical Pharmacology of Pentosan Polysulfate,” 17(2):186-198. (1991).Applicant
• Boulay, JP, et al., “Medical Therapy of Osteoarthritis in Dogs,” Vet. Exchange, 17:1-20 (1995).Applicant
• Bucci, LR, “Trace minerals,” Nutrition Applied to Injury Rehabilitation and Sports Medicine (CRC Press Inc,. Boca Raton, FL) p. 144 (1995).Applicant
• Capretto, C., et al., “A Double-Blind controlled study of S-Adenosylmethionine (SAMe) v. Ibruprofen in gonarthrosis, coxarthrosis and spondylarthrosis,” Clinical Trials Journal, 22(1): 15-24 (1985).Applicant
• Caruso, I., et al., “Double-blind study of S-Adenosyl-methionine versus placebo in hip and knee arthrosis” Biological Methylation and Drug Design Experimental and Clinical Role of S-Adenosyl-L-methionine, Brochardt ,RT, Creveling, CR, Ueland, PM, eds. (Humana Press, Clifton, NJ) (1986).Applicant
• Feo, F., et al., “The variations of S-adenosly-L-methionine content modulate hepatocyte growth during phenobarbital promotion of diethylnitrosamine-induced rat liver carcinogenesis,” Toxicologic Pathology, 15(1):109-114 (1987).Applicant
• Garcea, R., et al., “Inhibition of promotion and persistent nodule growth by S-Adenosyl-L-methionine in rat liver carcinogenesis: role of remodeling and apoptosis,” Cancer Research, 49:1850-1856 (1989).Applicant
• Guilidori, P., et al., “Transmethylation, transsulfuration and aminopropylation reactions of S-Adenosyl-L-methionine in vivo,” J Biol Chem, 259(7):4205-4211 (1984).Applicant
• Gloriso, S., et al., “Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis,” Int J Clin Pharm Res, V(1):39-49 (1985).Applicant
• Hanson, RR, “Mode of action of oral chondroprotective agents in equine practice,” Equine Practice, 17(9):19 (1995).Applicant
• Marcolongo, R., et al. , “Double-blind multicentre study of the activity of S-adenosyl-methionine in hip and knee osteoarthritis,” Current Therapeutic Research, 37(1):82-94 (1985).Applicant
• Vendemiale, G., et al., “Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease,” Scand J Gastroenterol, 24:407-415 (1989).Applicant
• H. Ralph Schumacher, Jr., “Crystals, Inflammation, and Osteoarthritis,” Osteoarthritis: The New Clinical Picture, Pathogenesis, and Management with Studies on a New Therapeutic Agent, S-Adenosylmethionine, The American Journal of Medicine, vol. 83(5A), Nov. 20, 1987 at 11.Applicant